1. Home
  2. UEIC vs VERU Comparison

UEIC vs VERU Comparison

Compare UEIC & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Electronics Inc.

UEIC

Universal Electronics Inc.

HOLD

Current Price

$3.59

Market Cap

48.3M

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.15

Market Cap

39.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEIC
VERU
Founded
1986
1971
Country
United States
United States
Employees
3838
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.3M
39.8M
IPO Year
1993
1990

Fundamental Metrics

Financial Performance
Metric
UEIC
VERU
Price
$3.59
$2.15
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$9.25
$25.00
AVG Volume (30 Days)
81.8K
198.5K
Earning Date
02-19-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$390,997,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.35
N/A
52 Week Low
$2.69
$2.10
52 Week High
$11.27
$14.20

Technical Indicators

Market Signals
Indicator
UEIC
VERU
Relative Strength Index (RSI) 64.13 35.09
Support Level $3.07 $2.23
Resistance Level $3.15 $2.42
Average True Range (ATR) 0.14 0.18
MACD 0.05 0.00
Stochastic Oscillator 98.36 8.21

Price Performance

Historical Comparison
UEIC
VERU

About UEIC Universal Electronics Inc.

Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Share on Social Networks: